The effect of hepatitis C virologic clearance on cardiovascular disease biomarkers in human immunodeficiency virus/hepatitis C virus coinfection

Open Forum Infectious Diseases

Volumn 1, Issue 3, 2014, Pages

  Chew, Kara W ^a   Hua, Lei ^b,g   Bhattacharya, Debika ^a   Butt, Adeel A ^c,d   Bornfleth, Lorelei ^a   Chung, Raymond T ^e   Andersen, Janet W ^f   Currier, Judith S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d SHEIKH KHALIFA MEDICAL CITY   (United Arab Emirates)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^g VERTEX PHARMACEUTICALS   (United States)

Author keywords

Cholesterol; HIV HCV coinfection; Macrophage activation; Sustained virologic response; Vascular adhesion molecules

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD14 ANTIGEN; CD163 ANTIGEN; D DIMER; GLUCOSE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONSTEROID ANTIINFLAMMATORY AGENT; PADGEM PROTEIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUSTAINED VIROLOGIC RESPONSE; TURBIDIMETRY; VIRAL CLEARANCE; VIRAL PHENOMENA AND FUNCTIONS;

EID: 84978328156     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofu104     Document Type: Article

References (40)

1. Hernando V, Perez-Cachafeiro S, Lewden C, et al. All-cause and liver-related mortality in HIV positive subjects compared to the general population: differences by HCV co-infection. J Hepatol 2012; 57:743-51.
2. Branch AD, Van Natta ML, Vachon ML, et al. Mortality in hepatitis C virus-infected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis 2012; 55:137-44.
3. Butt AA, Xiaoqiang W, Budoff M, et al. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009; 49:225-32.
4. Freiberg MS, Chang CC, Skanderson M, et al. The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circ Cardiovasc Qual Outcomes 2011; 4:425-32.
5. Tsui JI, Whooley MA, Monto A, et al. Association of hepatitis C virus seropositivity with inflammatory markers and heart failure in persons with coronary heart disease: data from the Heart and Soul study. J Card Fail 2009; 15:451-6.
6. Liao CC, Su TC, Sung FC, et al. Does hepatitis C virus infection increase risk for stroke? A population-based cohort study. PLoS One 2012; 7: e31527.
7. Kovacs A, Al-Harthi L, Christensen S, et al. CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis 2008; 197:1402-7.
8. Gonzalez VD, Falconer K, Blom KG, et al. High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol 2009; 83:11407-11.
9. Berenguer J, Rodriguez E, Miralles P, et al. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with human immunodeficiency virus and hepatitis c virus. Clin Infect Dis 2012; 55:728-36.
10. Castera L, Hezode C, Roudot-Thoraval F, et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 2004; 53:420-4.
11. Conjeevaram HS, Wahed AS, Afdhal N, et al. Changes in Insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Gastroenterology. 2011; 140:469-77.
12. Corey KE, Kane E, Munroe C, et al. Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology 2009; 50:1030-7.
13. Malaguarnera M, Giugno I, Trovato BA, et al. Lipoprotein(a) concentration in patients with chronic active hepatitis C before and after interferon treatment. Clin Ther 1995; 17:721-8.
14. Polgreen PM, Fultz SL, Justice AC, et al. Association of hypocholesterolaemia with hepatitis C virus infection in HIV-infected people. HIV Med 2004; 5:144-50.
15. Reingold J, Wanke C, Kotler D, et al. Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr 2008; 48:142-8.
16. Ford ES, Greenwald JH, Richterman AG, et al. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS 2010; 24:1509-17.
17. Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7: e44454.
18. Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204:1227-36.
19. Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. JAMA 2012; 308:379-86.
20. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203:780-90.
21. Kelesidis T, Kendall MA, Yang OO, et al. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012; 206:1558-67.
22. Rode A, Nicoll A, MollerHJ, et al. Hepatic macrophage activation predicts clinical decompensation in chronic liver disease. Gut 2013; 62:1231-2.
23. Sandler NG, Koh C, Roque A, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011; 141:1220-30, 1230.e1-3.
24. Chung RT, Umbleja T, Chen JY, et al. Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients. HIV Clin Trials 2012; 13:70-82.
25. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1997; 96:4219-25.
26. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101:1767-72.
27. Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation 2001; 103:491-5.
28. Caslake MJ, Packard CJ, Robertson M, et al. Lipoprotein-associated phospholipase A(2), inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Atherosclerosis 2010; 210:28-34.
29. Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104:1336-42.
30. Masia M, Padilla S, Robledano C, et al. Evaluation of endothelial function and subclinical atherosclerosis in association with hepatitis C virus in HIV-infected patients: a cross-sectional study. BMC Infect Dis 2011; 11:265.
31. Masia M, Robledano C, Lopez N, et al. Treatment for hepatitis C virus with pegylated interferon-(alpha) plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and-uninfected patients. J Antimicrob Chemother 2011; 66:1861-8.
32. Ronsholt FF, Ullum H, Katzenstein TL, et al. Persistent inflammation and endothelial activation in HIV-1 infected patients after 12 years of antiretroviral therapy. PLoS One 2013; 8:e65182.
33. Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. J Infect Dis 2014; 210:1248-59.
34. Nordell AD, McKenna M, Borges AH, et al. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc 2014; 3:e000844.
35. Schmidt C, Hulthe J, Fagerberg B. Baseline ICAM-1 and VCAM-1 are increased in initially healthy middle-aged men who develop cardiovascular disease during 6.6 years of follow-up. Angiology 2009; 60: 108-14.
36. Guzman-Fulgencio M, Berenguer J, de Castro IF, et al. Sustained virological response to interferon-alpha plus ribavirin decreases inflammation and endothelial dysfunction markers in HIV/HCV co-infected patients. J Antimicrob Chemother 2011; 66:645-9.
37. de Castro IF, Micheloud D, Berenguer J, et al. Hepatitis C virus infection is associated with endothelial dysfunction in HIV/hepatitis C virus coinfected patients. AIDS 2010; 24:2059-67.
38. Rotman Y, Liang TJ. Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol 2009; 83:7366-74.
39. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308:2584-93.
40. Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9:509-16.e1.